Next Article in Journal
MRI-Based Radiomics Differentiates Skull Base Chordoma and Chondrosarcoma: A Preliminary Study
Previous Article in Journal
Tumour Burden Reporting in Phase III Clinical Trials of Metastatic Lung, Breast, and Colorectal Cancers: A Systematic Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 13
10.3390/cancers14133263
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Regulation and Function of Matrix Metalloproteinase-13 in Cancer Progression and Metastasis

by
Shun Li
1,
David Mark Pritchard
2 and
Lu-Gang Yu
1,*
1
Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3BX, UK
2
Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3BX, UK
*
Author to whom correspondence should be addressed.
Cancers 2022, 14(13), 3263; https://doi.org/10.3390/cancers14133263
Submission received: 6 June 2022 / Revised: 28 June 2022 / Accepted: 1 July 2022 / Published: 3 July 2022
(This article belongs to the Section Molecular Cancer Biology)
Browse Figures
Versions Notes

Abstract

:

Simple Summary

MMP-13 is an enzyme that can digest and disrupt the tissue structures surrounding epithelial cells that line the surface of many internal organs, as well as the tissue structures surrounding endothelial cells that line the surface of blood vessels. The production of MMP-13 is tightly controlled in physiological conditions but is increased in various cancers and plays multiple roles in tumour progression and metastasis. This review summarises the current understanding of the regulation of MMP-13 production and discusses the actions of MMP-13 in cancer progression and metastasis.

Abstract

Matrix metalloproteinase-13 (MMP-13) is a member of the Matrix metalloproteinases (MMPs) family of endopeptidases. MMP-13 is produced in low amounts and is well-regulated during normal physiological conditions. Its expression and secretion are, however, increased in various cancers, where it plays multiple roles in tumour progression and metastasis. As an interstitial collagenase, MMP-13 can proteolytically cleave not only collagens I, II and III, but also a range of extracellular matrix proteins (ECMs). Its action causes ECM remodelling and often leads to the release of various sequestered growth and angiogenetic factors that promote tumour cell growth, invasion and angiogenesis. This review summarizes our current understanding of the regulation of MMP-13 expression and secretion and discusses the actions of MMP-13 in cancer progression and metastasis.

1. Introduction

Matrix metalloproteinases (MMPs) are a family of 28 (so far) zinc-dependent endopeptidases [1]. According to their substrate specificities, MMPs are divided into several subfamilies of collagenases (MMP-1, MMP-8, MMP-13 and MMP-18), matrilysins (MMP-7 and MMP-26), gelatinases (MMP-2 and MMP-9), stromelysins (MMP-3, MMP-10 and MMP-11), membrane-type MMPs (MT-MMPs), glycosylphosphatidylinositol-anchored MMPs (MMP-17 and MMP-25) and others (MMP-12, MMP19, MMP-20, MMP-21, MMP-22, MMP-23, MMP-27 and MMP-28) [2,3,4]. All MMP family members share a conventional structure of a catalytic domain and a pro-peptide domain. In all cases except MMP-7 and MMP-26, the catalytic domain of MMPs contains a zinc-binding motif HEXXHXXGXXH [5] and is linked to a hemopexin domain by a flexible hinge region. With the exception of MMP-23, whose cysteine residue is located in a different amino acid sequence [6], the MMP amino-terminal pro-peptide domain contains a consensus sequence PRCXXPD (also known as cysteine switch). MMPs are produced in low amounts, and this is well-regulated under normal physiological conditions by various factors, including endogenous MMP inhibitors and tissue inhibitors of MMPs (TIMPs) [7]. Some MMP family members are, however, overexpressed in pathological disorders, such as cancer [8,9,10]. They are considered to be the primary contributors to the degradation of extracellular matrix (ECM) in tumour cell invasion. MMP family members have the ability to cleave ECM molecules with a wide range of substrate specificities [11]. Most ECM components can be degraded by MMP-3, -7, -10 and -11, while other MMPs, such as MMP-1, -8 and -13, preferentially digest collagen I, II and III located near the cells.
MMP-13 is an interstitial collagenase (also known as collagenase 3) and is overexpressed in various cancers [12,13,14] and in cancer stromal cells [15]. As a collagenase, MMP-13 can cleave not only collagens I, II and III, but also a wide range of ECM components. The expression and secretion of MMP-13 are regulated at the transcriptional and cellular levels [14,16,17,18,19,20]. Considerable evidence has shown that MMP-13-mediated degradation and remodelling of ECM plays a very important role in cancer pathogenesis and metastasis.

2. MMP-13 Structure

MMP-13 is a 53kDa protein that consists of four domains, namely, the N-terminal signal sequence, basic pro-domain, catalytic domain and C-terminal hemopexin-like domain (Figure 1). Its C-terminal hemopexin-like domain is linked to the catalytic domain by a flexible hinge region. Its signal peptide domain controls the movement of the newly synthesized molecule and guides it to the endoplasm reticulum, while its pro-domain, which contains a zinc-interacting thiol (SH) group, keeps MMP-13 as an inactive zymogen form of pro-MMP-13. The catalytic domain of MMP-13 is shielded by the pro-domain in the inactive pro-MMP-13, and this prevents substrate access [21]. The MMP-13 catalytic domain, which is highly conserved among MMPs, includes three α-helixes and five β-sheets connected by eight loops [22]. The highly conserved catalytic domain of MMP-13, like other MMP members, has an extended zinc-binding motif, which consists of three zinc-binding histidines and a glutamate, a second structural zinc ion and three structural calcium ions, which are essential for enzyme stability [23,24]. The MMP-13 C-terminal hemopexin-like domain consists of four β-propeller elements and functions primarily for substrate specificity [25], as well as for degradation of triple-helical collagens [26]. Activation of pro-MMP-13 is carried out by other MMPs, such as MT1-MMP or MMP-2, on the cell surface [27], in which the cysteine residue is pulled out by conformational change to generate a functional active site, and this, in turn, enables enzymes to remove the pro-domain completely [28].
MMP-13 substrate specificity is largely controlled by its S pockets in the catalytic domain. There are multiple S pockets sitting on two sides of the catalytic zinc ion: (1) on the left side are pockets without a prime: S1, S2, S3…Sn; (2) on the right side are pockets with a prime: S1′, S2′, S3′… Sn’ [29]. The substances or inhibitors, in correspondence with the specific pockets, are named P1, P2…. Pn and P1′, P2′…Pn’, respectively [30]. It is believed that the S1′ pocket is the key contributor to establish MMP binding specificity, possibly because it is the most variable in depth among all the pockets [31]. While all MMPs contain the S1′ pocket, the volume and shape of each S1′ pocket varies [31]. MMP-13 possesses an exceptionally large S1′ pocket made of residues 245–253 [20]. However, given that MMP-13, MMP-8 and MMP-1 are all collagenases, but MMP-1 has only a small shallow pocket, the S1′ pocket of these MMP members may not be the only determining factor for their collagenase activity.

3. Regulation of MMP-13 Expression and Secretion

Due to its destructive nature as a protease towards a wide range of ECM proteins, MMP-13 was initially thought to be absent or to lack steady production in normal tissues [32,33]. However, subsequent studies revealed that MMP-13 is expressed in human chondrocytes and other healthy human connective tissues, such as cartilage and developing bone [34]. MMP-13 is also detected in normal epithelial and neuronal cells [35]. However, the expression and secretion of MMP-13 in normal human tissues are low and are tightly controlled at multiple levels by multiple factors.
The promoter of the human MMP-13 gene contains several binding sites for transcription factors. This includes a PEA-3 binding site and an AP-1 consensus sequence [36]. The combination of PEA-3/AP-1 acts as a responsive unit to growth factors, oncogenes and tumour promoters [36]. The human MMP-13 promoter also contains an osteoblast-specific element (OSE-2) binding site, ACCACA, which can be bound by transcription factor Cbfal [37]. The more distal region of the MMP-13 promoter also contains a Transforming growth factor-beta inhibitory element (TIE) binding site [38]. A conserved forkhead response element (FHRE) consensus sequence for FOXO3a has also been reported in the MMP-13 promoters in humans, mice and rats [39]. Although the precise mechanisms of MMP-13 regulation at the transcriptional level remain largely unknown, the presence of multiple bindings sites in its promoter for several transcription factors clearly indicates the importance of MMP-13 regulation at the transcriptional level. Indeed, several transcription factors have been reported to regulate MMP-13 expression. For example, the binding of ETS variant transcription factor 4 (ETV4) to the AP-1 binding site in the MMP-13 promoter region induced MMP-13 expression in breast cancer [40]. The binding of Small leucine zipper protein (sLZIP) to MMP-13 promoter increased MMP-13 expression in prostate cancer cells [41].
Various hormones, cytokines and growth factors regulate MMP-13 expression in human tissues. Interleukin-1 (IL-1), Interleukin-6 (IL-6) and Tumour necrosis factor alpha (TNF-α) can induce MMP-13 expression in primary chondrocytes [42]. This process is reported to involve nuclear translocation of nuclear factor kappa B (NF-κB) [43]. Growth factors, such as insulin-like growth factors (IGF)-I and -II, can inhibit MMP-13 expression in chondrocytes [44], while transforming growth factor-β1 (TGF-β1) has been shown to induce MMP-13 expression in human KMST fibroblasts [45].
MMP-13 is normally secreted as an inactive pro-MMP-13 form by cells. Its activation is carried out through proteolytic cleavage of its pro-peptide domain by MT1-MMP and MMP-2 [27,46,47] (Figure 2). MMP-13 can also be activated by MMP-3 [27] and the major isoenzyme of human tumour-associated trypsinogen, trypsin-2 [48]. The activity of MMP-13 is controlled by TIMPs. Four TIMPs (TIMP1, TIMP2, TIMP3 and TIMP4) are known to exist in human tissues [49]. Each TIMP contains an N-terminal ‘wedge-shaped’ ridge domain, which binds to the MMP’s active site, and a C-terminal hemopexin interaction domain [50]. The function of TIMPs is to block substrate access to MMPs. In addition to the tight control of its expression and activity in normal physiological conditions, the secretion of MMP-13 to the outside of cells is also regulated by endocytosis. Low-density lipoprotein receptor-related protein 1 (LRP1) can bind to secreted MMP-13 (both pro- and activated forms) through its hemopexin domain and induce MMP-13 endocytosis and subsequent degradation in lysosomes in healthy human chondrocytes [34].
In cancer, the tight control of MMP-13 production and activity is disrupted by intrinsic or extrinsic mechanisms. The intrinsic mechanisms include changes of expression of oncogenes (e.g., Ror2) or proto-oncogenes (e.g., c-fos) and tumour suppressor genes (e.g., p53), which directly activate MMP-13 expression [51]. Suppression of oncogene Ror2 expression downregulated MMP-13 expression in osteosarcoma SaOS-2 cells [52]. Suppression of oncogene Golgi membrane protein 1 (GOLM1) inhibited MMP-13 expression in breast cancer [53], while suppression of tumour suppressor p53 increased MMP-13 expression in squamous cell carcinomas [54]. The extrinsic mechanisms involved in MMP-13 regulation include hypoxia and inflammation. The hypoxic microenvironment inside a tumour, created by a restricted oxygen supply from the increasing tumour size, induces cell necrosis [55]. This triggers inflammation and attracts leukocytes to the area to produce cytokines such as IL-1, IL-6 and TNF-α [56]. As discussed above, cytokines such as IL-1, IL-6 and TNF-α, β are important MMP-13 expression enhancers [42,51,57]. The secretion of these cytokines leads to an increase in MMP-13 expression [58,59,60]. Tumour hypoxia can also trigger the expression of hypoxia-inducible transcription factor (HIF)-1, which directly promotes MMP-13 gene expression by binding to the MMP-13 promotor or indirectly through promotion of the expression of the growth factors or cytokines [61] that regulate MMP-13 expression.
Recent studies have also reported the regulation of MMP-13 expression in cancer by other effectors, such as chemokines and endogenous enzymes. The binding of chemokine CCL17 to its receptor CCR4 was shown to enhance MMP-13 expression in bladder cancer through the activation of extracellular signal-regulated kinase (ERK) 1/2 signalling [62], and in colorectal cancer through the activation of ERK/NF-κB signalling [63]. The upregulation of ERK/NF-κB signalling enhanced the binding of NF-κB to Inhibitor of growth 2 (ING2) promoter, leading to the activation of ING2, which subsequently increased MMP-13 expression in colon cancer [64]. Small ubiquitin related modifier (SUMO)-specific protease 2 (SENP2) altered SUMOylation of the MMP-13 promoter and enhanced MMP-13 expression in bladder cancer [65]. FTO, a demethylase for N6-methyladenosine modification, was also shown to upregulate MMP-13 expression in oesophageal squamous cell carcinoma [66]. Overall, the expression, secretion and activation of MMP-13 in cancer is regulated at multiple levels and by many molecules, including cytokines, growth factors and proteases.

4. MMP-13 Expression in Cancer

Given its powerful and destructive action toward ECM, it is not surprising that higher MMP-13 expression frequently occurs in cancer. MMP-13 overexpression in cancer was first reported in breast cancer [12] and has subsequently been observed in many other cancers, such as colorectal [67,68], prostate [69], oesophageal [70,71], thyroid [72] and gastric cancers [73], as well as multiple myeloma (MM) [74] (Table 1). Over 50% higher MMP-13 expression is seen in bladder and non-small cell lung cancers [75], particularly at the invading front of the tumours [14]. A high level of MMP-13 expression was not only detected in primary breast cancers but also in metastatic lymph nodes that are associated with cancer aggressiveness [13,76]. Moreover, even higher MMP-13 expression is seen in the stromal cells surrounding the tumour [15]. Aggressive cancers have been shown to express higher levels of MMP-13 than less aggressive ones in prostate [77], breast [78] and head and neck cancers (HNSCC) [14,79]. Higher MMP-13 expression is also associated with lymph node metastasis and poor prognosis in bladder and non-small cell lung cancers [75,80] and with poorer patient survival in breast, prostate and head and neck cancers [14,78,79]. Overall, MMP-13 overexpression occurs in various cancers, including many common cancer types, and is often associated with tumour aggressiveness, poorer prognosis and reduced patient survival.

5. MMP-13 in Tumour Growth

The ECM contains multiple complex macromolecule components, such as collagens, proteoglycans and glycoproteins, and provides the scaffold support to tissues and organs [83]. ECM also helps to create an adequate environment for cell adhesion and tissue development. ECM generally consists of an architecture of fibrous polymers (e.g., collagens, elastins and resilins) [84] embedded in an undefined-shaped mixture of nonfibrous components (e.g., proteoglycans) [85]. ECM also includes basement membranes that are comprised of glycoproteins, such as laminin, fibronectin and entactin [86,87]. ECM component proteins are large multifunctional molecules with multiple domains. These domains are responsible for various functions, such as molecular recognition by cell surface receptors, predisposition to oligomerize and recognition by MMPs [88]. ECM serves as a general reservoir for growth factors and normally sequesters them in non-bioavailable forms. It also provides binding sites to cell surface adhesion molecules, such as integrins, for cell attachment and adhesion [89]. ECM degradation by MMPs such as MMP-13 releases sequestered growth factors, such as fibroblast growth factors (FGF) and TGF, which aid tumour cell proliferation [90]. MMP-mediated ECM degradation can also reveal the survival-associated hidden binding sites on ECM to enable ECM interaction with integrins on the tumour cell surface [91]. Although MMP-13 as a protease predominately degrades types I, II and III collagens, it can also cleave a range of other ECM components, such as gelatins [92], large tenascin C, fibronectin [93], aggrecan [94], fibrillin-1 [95], osteonectin [96] and perlecan. Increased expression of MMP-13 in tumour or stromal cells alters the collagen concentration in ECM and creates a more favourable environment for tumour growth [97]. MMP-13 can also deactivate non-matrix proteins, such as MCP-3 and SDF-1, by proteolytic actions [98,99,100] and reduce immune cell infiltration into the tumour and promote tumour growth [101].
Overexpression of MMP-13 mediated by GOLM1, C1r and Leptin has been shown to increase tumour growth in breast cancer [53], cutaneous squamous cell carcinoma [102] and pancreatic cancer [103]. The inhibition of MMP-13 expression by hammerhead ribozyme suppresses squamous cell carcinoma tumour growth and reduces the number of proliferating cells within the tumours [104]. Oral administration of an MMP-13 inhibitor, CMPD-1, twice a day, markedly delayed the growth of breast tumours in syngeneic mice [105]. Suppression of MMP-13 expression by antisense ribozyme reduced squamous cell carcinoma growth and led to the inhibition of cell invasion and induction of cell apoptosis [104]. The inhibition of MMP-13 expression by interferon gamma (IFN-γ) via activation of ERK1,2 and STAT1 in human cutaneous SCC cells (UT-SCC-7) and Ras-transformed human epidermal keratinocytes (A-5 cells) reduced cell proliferation and induced apoptosis [106]. MMP-13 suppression, mediated by p53 in malignantly transformed squamous epithelial cells, displayed an initial anti-invasive effect and was followed by induction of cell death [54]. Together, these studies indicate that overexpression of MMP-13 in cancer, either by tumour cells or stromal cells in the tumour microenvironment, makes important contributions to tumour growth.

6. MMP-13 in Cancer Cell Invasion and Metastasis

Tumour cell infiltration into ECM is a critical early step during cancer invasion and metastasis. Degradation of ECM by proteases such as MMPs creates the pathway for tumour cell infiltration and plays a key role in this process. Each MMP family member has its own substrate specificities towards ECM components. For example, MMP-1 targets primarily collagen III, while MMP-3 and -10 preferentially degrade proteoglycans, fibronectin and laminin [107]. MMP-13 has a relatively broad target specificity and can degrade collagens I, II and III, as well as a range of other ECM components [93,94,95,108]. For example, MMP-13 can cleave ECM component Laminin-5, which is mostly expressed in the basement membrane and is responsible for static adhesion of the epidermis and dermis for hemidesmosome formation [109,110,111]. Laminin-5 cleavage can reveal cryptic sites and increase mobility of epithelial cancer cells in tumour cell invasion and tissue remodelling [112,113,114]. MMP-13 is also involved in the activation of other MMPs, such as MMP-2 and MMP-9, by cleavage of the inactive pro-MMP-2 and pro-MMP-9 forms [19,115]. Proteolytic activation of MMP-9 by MMP-13 occurs in osteoarthritic chondrocytes [116] and chronic periodontitis [117]. It is possible that such an MMP-13/MMP-9 activation cascade may also exist in cancer.
MMP-13 also contributes to Epithelial-to-mesenchymal transition (EMT) in the tumorigenesis of epithelial cancer [118]. EMT confers epithelial cells with the metastatic properties of increased mobility and invasion, as well as an ability to escape apoptosis [119]. A primary EMT inducer is TGF-β [120]. The release of active TGF-β is normally carried out through proteolytical cleavage of the TGF-β-complex by MMP-28 [121]. Similar TGF-β activation has been reported by MMP-13 with chondrocytes in matrix vesicles, where secreted MMP-13 activated latent TGF-β in the progress of mineralization of growth plate cartilage [122]. The inhibition of MMP-13 expression in breast cancer cells at the tumour–bone interface significantly reduced TGF-β signalling, leading to a decrease in tumour-induced osteolysis [123].
MMP-13 also participates in the process of tumour cell infiltration into the blood or lymphatic vessels during metastasis. The blood capillaries are composed of an endoluminal side formed by endothelial cells and an abluminal side containing a basement membrane and vascular smooth muscle cells [124]. MMPs assist tumour cell penetration into blood capillaries by degrading the vascular basement membrane. MMP-9 is the primary contributor to vascular basement membrane degradation [125]. As MMP-13 is capable of activating MMP-9 by cleavage of the inactive pro-MMP-9 form [115,126,127], its action on MMP-9 activation can therefore promote tumour cell infiltration into the blood/lymphatic vessels at primary tumour sites, as well as the extravasation of invaded tumour cells from blood/lymphatic vessels at remote organs. The discovery that the inhibition of MMP-13 expression in MC38 colon cancer cells decreased the number of tumour cells extravasated from the hepatic vasculature in an experimental metastasis model is in line with this possibility [128].
Bone is one of the preferential metastasis sites of cancers such as breast cancer [129]. The bone ECM is rich with type I collagens [130]. MMP-13 is believed to be the primary protease to degrade type I collagen and aids breast cancer bone metastasis [131,132]. A higher MMP-13 level occurs at the tumour–bone interface of breast cancer [133]. Soluble factors, such as IL-6, produced by breast cancer cells induce MMP-13 expression in osteoblasts [134]. Tumour cells also produce parathyroid hormone-related protein (PTHrP) to induce MMP-13 expression through the activation of protein kinase C (PKC)-ERK1/2 signalling [135]. Inflammatory cells or osteoblasts could also produce PTHrP to stimulate MMP-13 secretion to promote breast cancer bone metastasis [136]. MMP-13 is also detected at the MM and bone marrow interface, and its presence is shown to promote MM cell bone marrow infiltration [137] and induce osteoclast [138]. Injection of MMP-13-selective inhibitor Zn2+-chelating compound, which targets the catalytic domain of MMP-13 [139], significantly reduced the level of bone destruction and delayed MM growth in an immunocompetent syngeneic mouse model with multiple myeloma [74].
The arrival of tumour cells at distant organs, which is an alien microenvironment from the primary tumour sites, is often unfavourable for tumour cells to survive and grow. This can lead the tumour cell to die from apoptosis or enter a ‘silent’ mode without proliferation or death. The successful establishment of a metastasis at the distant organs/sites requires the build-up of a permissive environment, known as a pre-metastatic niche. Pre-metastatic niche formation is driven by many factors, including primary tumour-derived factors, tumour-mobilized bone marrow-derived cells (BMDC), hypoxia, ECM remodelling and exosomes [140]. The formation of a pre-metastatic niche is triggered by the release from the primary tumour of factors such as growth factors (e.g., TGF-α and -β) or cytokines (e.g., TNF-α). These, in turn, induce the expression and secretion of chemoattractants (e.g., S100 proteins) by the endothelium [141] and the production of fibronectin by fibroblasts at the niche site [142]. The expression of S100 can lead to the activation of NF-κB signalling [143] and the subsequent production of MMPs, including MMP-13, by stromal cells [144]. The structure of the new site’s intrinsic ECM is often less ideal for attachment, metabolism and migration of the recruited BMDC and immune cells. The production and action of the new MMPs, including MMP-13, cause ECM remodelling and aid the formation of the pre-metastatic niche. BMDCs and several immune cells are also recruited to the site to assist in the establishment of the pre-metastatic niche. These immune cells secrete inflammatory cytokines, growth factors and proangiogenic molecules to create a favourable local microenvironment for the extravasated tumour cells [145]. MMP-9 is responsible for the recruitment of BMDCs to the niche site via releasing soluble factors, such as Kit-ligand from BM stromal cells [146], and can be activated by MMP-13 through proteolytic cleavage of pro-MMP-9.
Lysl Oxidase (LOX) is another key regulator involved in the recruitment of BMDCs and is often released by primary tumours during hypoxia [147]. LOX cross-links collagen IV in the basement membrane and allows CD11b+ myeloid cells to adhere and release MMPs at the niche site [147]. The release of these MMPs further degrades collagen fibres and releases collagen IV peptides, which act as chemoattractants to aid recruitment of BMDCs to the niche site. As the inhibition of LOX by licofelone can reduce MMP-13 expression in human osteoarthritic chondrocytes [148], LOX-mediated MMP-13 expression can therefore contribute to pre-metastatic niche formation by aiding BMDC recruitment to niche sites.
Exosomes are small vesicles that contain proteins, mRNAs, microRNAs, small RNAs and DNA fragments [149]. Tumour-associated exosomes can assist pre-metastatic niche formation and aid tumour cell communication by transportation of regulatory molecules [150,151]. MMP-13 occurs in primary tumour cell-derived exosomes under hypoxic conditions [152]. It is later released into the circulation to modulate ECM components and helps the establishment of pre-metastasis sites [152]. Overall, MMP-13 makes important contributions to tumour cell invasion at primary tumour sites, as well as the establishment of tumour cells at remote organs in metastasis through the degradation and remodelling of ECM and the activation of other MMPs.

7. MMP-13 in Angiogenesis

Angiogenesis is an important process during cancer pathogenesis. It provides essential nutrients and a blood supply for sustained tumour growth and development [153]. The multiple-stepped process of angiogenesis consists of: (1) degradation of basement membrane and ECM around the blood vessels; (2) activation of endothelial cells for migration and proliferation; (3) transformation of endothelial cells into capillary tubes [154]. Angiogenesis is tightly regulated in normal tissues, but this tight control is disrupted in cancer [155] by a group of angiogenic factors released by endothelial cells, tumour cells, stromal cells and ECM [156,157,158,159,160]. These angiogenic factors can be either pro- or anti-angiogenic [161]. Pro-angiogenetic regulators include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), TGF-α and -β, epidermal growth factor (EGF), platelet-derived growth factor (PDGF), placental-derived growth factor and angiopoietin -1 and -2 [162], while anti-angiogenic regulators include angiostatin, endostatin, tumstatin, platelet factor-4, interleukin-12, thrombospondin-1, TIMPs and interferon-α, -β and -γ [154].
Many MMP family members are known to take part in the process of angiogenesis. Their primary action is to degrade ECM components. This leads to the release of ECM-bound angiogenic factors that enable endothelial cells to invade the tumour stroma leading to new blood vessel formation [163]. Interstitial collagens are the major proteins in the vascular tissue milieu [164]. The structural triple-helical, fibrillar collagen in vascular tissue is highly resistant to many proteolytic enzymes, such as trypsin, plasmin, extracellular serine proteases and many MMP members [165]. Only a limited number of MMPs can cleave the highly structured fibrillar collagens. MMP-2 and -9 can cleave fibrillar type I collagen and release ECM-bound angiogenic growth factors [88] to aid blood vessel formation and endothelial cell invasion [166,167]. MMP-13 is one of the proteases that can digest well-structured fibrillar collagens in ECM around the blood vessel and contribute to the release of ECM-bound angiogenic regulators [168]. MMP-13 has been shown to efficiently and specifically cleave interstitial collagens to initiate ECM remodelling and promote new blood vessel formation in the chorioallantoic membrane in a chicken embryo model [164]. MMP-13 expression in stromal fibroblasts was shown to enhance VEGF and VEGFR-2 concentrations in the tumour cell invasive areas around blood vessels and promote angiogenesis in skin carcinoma [169]. MMP-13-mediated release of VEGF-C increased cancer cell spreading through lymphatic vascular systems in paediatric multiple myeloma [170]. Higher MMP-13 expression correlates closely with a higher number of blood vessels in human head and neck cancer [168]. Overall, the expression and presence of MMP-13 in cancer and stromal cells is actively involved in promoting angiogenesis in tumour cell metastatic spreading.

8. Concluding Remarks

As an interstitial collagenase that can cleave not only collagens but also a range of other ECM components, MMP-13 is overexpressed in various cancers and plays multiple roles in cancer development, progression and metastasis. Its proteolytic action leads to ECM remodelling and release of ECM-sequestered growth factors, cytokines and angiogenic factors that promote tumour cell proliferation, EMT, invasion and angiogenesis. MMP-13-mediated ECM remodelling and release of growth factors also aids the recruitment of immune cells to the pre-metastatic niche and helps the establishment of secondary metastasis sites in distant organs (Figure 3). Despite the critical involvement of MMP-13 in cancer progression and metastasis, the precise mechanisms of its regulation and actions are still not fully understood. Much also remains unknown about the possible coordination of MMP-13 action with other MMP family members during cancer pathogenesis. Little is known about whether MMP-13 appearance/overexpression in cancer and stromal cells influences the activity or function of cell surface molecules, such as cell adhesion and signalling proteins. Future research will help to gain further insights into the role and actions of MMP-13 in cancer and determine whether MMP-13 represents an effective therapeutic target for this disease.

Author Contributions

Conceptualization, S.L. and L.-G.Y.; writing—original draft preparation, S.L.; writing—review and editing, S.L., D.M.P. and L.-G.Y. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

bFGFBasic fibroblast growth factor
BMDCBone marrow-derived cells
ECMExtracellular matrix
EGFEpidermal growth factor
EMTEpithelial-to-mesenchymal transition
ERExtracellular signal-regulated kinase
ETVETS variant transcription factor 4
FAKFocal adhesion kinase
FHREForkhead response element
FGFFibroblast growth factors
GOLM1Golgi membrane protein 1
HIFHypoxia-inducible transcription factor
HNSCCSquamous cell carcinoma of the head and neck
ILInterleukin
IFN-γInterferon gamma
ING2Inhibitor of growth 2
IGFInsulin-like growth factor
IFN-βInterferon β
LOXLysl Oxidase
MMPMatrix metalloproteinase
NF-κBNuclear factor kappa B
MMMultiple Myeloma
OSE-2Osteoblast-specific element
PDGFPlatelet-derived growth factor
PTHrPparathyroid hormone-related protein
PKCProtein kinase C
SHZinc-interacting thiol
SUMOSmall ubiquitin related modifier
SENP2SUMO-specific protease 2
TGF-βTransforming growth factor-β1
TIMPsTissue inhibitors of MMPs
TIETransforming growth factor-beta inhibitory element
TNF-αTumour necrosis factor alpha
VEGFVascular endothelial growth factor

References

  1. Coussens, L.M.; Fingleton, B.; Matrisian, L.M. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 2002, 295, 2387–2392. [Google Scholar] [CrossRef] [PubMed]
  2. Puente, X.S.; Sánchez, L.M.; Overall, C.M.; López-Otín, C. Human and mouse proteases: A comparative genomic approach. Nat. Rev. Genet. 2003, 4, 544–558. [Google Scholar] [CrossRef] [PubMed]
  3. Javaid, M.A.; Abdallah, M.N.; Ahmed, A.S.; Sheikh, Z. Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: An overview. Acta Neurol. Belg. 2013, 113, 381–390. [Google Scholar] [CrossRef] [PubMed]
  4. Zhong, Y.; Lu, Y.T.; Sun, Y.; Shi, Z.H.; Li, N.G.; Tang, Y.P.; Duan, J.A. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer. Expert Opin. Drug Discov. 2018, 13, 75–87. [Google Scholar] [CrossRef]
  5. Dufour, A.; Sampson, N.S.; Zucker, S.; Cao, J. Role of the hemopexin domain of matrix metalloproteinases in cell migration. J. Cell. Physiol. 2008, 217, 643–651. [Google Scholar] [CrossRef] [Green Version]
  6. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2, 161–174. [Google Scholar] [CrossRef]
  7. Kapoor, C.; Vaidya, S.; Wadhwan, V.; Kaur, G.; Pathak, A. Seesaw of matrix metalloproteinases (MMPs). J. Cancer Res. Ther. 2016, 12, 28–35. [Google Scholar] [CrossRef]
  8. Sorsa, T.; Tervahartiala, T.; Leppilahti, J.; Hernandez, M.; Gamonal, J.; Tuomainen, A.M.; Lauhio, A.; Pussinen, P.J.; Mäntylä, P. Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases. Therapeutic response to non-antimicrobial properties of tetracyclines. Pharmacol. Res. 2011, 63, 108–113. [Google Scholar] [CrossRef]
  9. Burrage, P.S.; Mix, K.S.; Brinckerhoff, C.E. Matrix metalloproteinases: Role in arthritis. Front. Biosci. 2006, 11, 529–543. [Google Scholar] [CrossRef] [Green Version]
  10. Huang, H. Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances. Sensors 2018, 18, 3249. [Google Scholar] [CrossRef] [Green Version]
  11. McCawley, L.J.; Matrisian, L.M. Matrix metalloproteinases: They’re not just for matrix anymore! Curr. Opin. Cell Biol. 2001, 13, 534–540. [Google Scholar] [CrossRef]
  12. Freije, J.M.; Díez-Itza, I.; Balbín, M.; Sánchez, L.M.; Blasco, R.; Tolivia, J.; López-Otín, C. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J. Biol. Chem. 1994, 269, 16766–16773. [Google Scholar] [CrossRef]
  13. Kotepui, M.; Punsawad, C.; Chupeerach, C.; Songsri, A.; Charoenkijkajorn, L.; Petmitr, S. Differential expression of matrix metalloproteinase-13 in association with invasion of breast cancer. Contemp. Oncol. 2016, 20, 225–228. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Johansson, N.; Airola, K.; Grénman, R.; Kariniemi, A.L.; Saarialho-Kere, U.; Kähäri, V.M. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am. J. Pathol. 1997, 151, 499–508. [Google Scholar]
  15. Uría, J.A.; Ståhle-Bäckdahl, M.; Seiki, M.; Fueyo, A.; López-Otín, C. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res. 1997, 57, 4882–4888. [Google Scholar]
  16. Sun, Y.; Cheung, J.M.; Martel-Pelletier, J.; Pelletier, J.P.; Wenger, L.; Altman, R.D.; Howell, D.S.; Cheung, H.S. Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J. Biol. Chem. 2000, 275, 11327–11332. [Google Scholar] [CrossRef] [Green Version]
  17. Pei, Y.; Harvey, A.; Yu, X.P.; Chandrasekhar, S.; Thirunavukkarasu, K. Differential regulation of cytokine-induced MMP-1 and MMP-13 expression by p38 kinase inhibitors in human chondrosarcoma cells: Potential role of Runx2 in mediating p38 effects. Osteoarthr. Cartil. 2006, 14, 749–758. [Google Scholar] [CrossRef] [Green Version]
  18. Yoon, S.W.; Chun, J.S.; Sung, M.H.; Kim, J.Y.; Poo, H. alpha-MSH inhibits TNF-alpha-induced matrix metalloproteinase-13 expression by modulating p38 kinase and nuclear factor kappaB signaling in human chondrosarcoma HTB-94 cells. Osteoarthr. Cartil. 2008, 16, 115–124. [Google Scholar] [CrossRef] [Green Version]
  19. Cowell, S.; Knäuper, V.; Stewart, M.L.; D’Ortho, M.P.; Stanton, H.; Hembry, R.M.; López-Otín, C.; Reynolds, J.J.; Murphy, G. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: Associated activation of gelatinase A, gelatinase B and collagenase 3. Biochem. J. 1998, 331 Pt 2, 453–458. [Google Scholar] [CrossRef] [Green Version]
  20. Leeman, M.F.; Curran, S.; Murray, G.I. The structure, regulation, and function of human matrix metalloproteinase-13. Crit. Rev. Biochem. Mol. Biol. 2002, 37, 149–166. [Google Scholar] [CrossRef]
  21. Van Wart, H.E.; Birkedal-Hansen, H. The cysteine switch: A principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA 1990, 87, 5578–5582. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Rangasamy, L.; Geronimo, B.D.; Ortín, I.; Coderch, C.; Zapico, J.M.; Ramos, A.; de Pascual-Teresa, B. Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs). Molecules 2019, 24, 2982. [Google Scholar] [CrossRef] [Green Version]
  23. Whittaker, M.; Floyd, C.D.; Brown, P.; Gearing, A.J. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 1999, 99, 2735–2776. [Google Scholar] [CrossRef] [PubMed]
  24. Murphy, G.; Nagase, H. Progress in matrix metalloproteinase research. Mol. Asp. Med. 2008, 29, 290–308. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Murphy, G.; Knäuper, V. Relating matrix metalloproteinase structure to function: Why the “hemopexin” domain? Matrix Biol. 1997, 15, 511–518. [Google Scholar] [CrossRef]
  26. Bode, W. A helping hand for collagenases: The haemopexin-like domain. Structure 1995, 3, 527–530. [Google Scholar] [CrossRef]
  27. Knäuper, V.; Will, H.; López-Otin, C.; Smith, B.; Atkinson, S.J.; Stanton, H.; Hembry, R.M.; Murphy, G. Cellular Mechanisms for Human Procollagenase-3 (MMP-13) Activation: Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J. Biol. Chem. 1996, 271, 17124–17131. [Google Scholar] [CrossRef] [Green Version]
  28. Grams, F.; Huber, R.; Kress, L.F.; Moroder, L.; Bode, W. Activation of snake venom metalloproteinases by a cysteine switch-like mechanism. FEBS Lett. 1993, 335, 76–80. [Google Scholar] [CrossRef] [Green Version]
  29. Gupta, S.P.; Patil, V.M. Specificity of binding with matrix metalloproteinases. Exp. Suppl. 2012, 103, 35–56. [Google Scholar]
  30. Liu, J.; Khalil, R.A. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders. Prog. Mol. Biol. Transl. Sci. 2017, 148, 355–420. [Google Scholar]
  31. Laronha, H.; Caldeira, J. Structure and Function of Human Matrix Metalloproteinases. Cells 2020, 9, 1076. [Google Scholar] [CrossRef] [PubMed]
  32. Vincenti, M.P.; Brinckerhoff, C.E. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: Integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res. Ther. 2002, 4, 157. [Google Scholar] [CrossRef] [PubMed]
  33. Wang, M.; Sampson, E.R.; Jin, H.; Li, J.; Ke, Q.H.; Im, H.-J.; Chen, D. MMP13 is a critical target gene during the progression of osteoarthritis. Arthritis Res. Ther. 2013, 15, R5. [Google Scholar] [CrossRef] [Green Version]
  34. Yamamoto, K.; Okano, H.; Miyagawa, W.; Visse, R.; Shitomi, Y.; Santamaria, S.; Dudhia, J.; Troeberg, L.; Strickland, D.K.; Hirohata, S.; et al. MMP-13 is constitutively produced in human chondrocytes and co-endocytosed with ADAMTS-5 and TIMP-3 by the endocytic receptor LRP1. Matrix Biol. 2016, 56, 57–73. [Google Scholar] [CrossRef]
  35. Cui, N.; Hu, M.; Khalil, R.A. Chapter One—Biochemical and Biological Attributes of Matrix Metalloproteinases. In Progress in Molecular Biology and Translational Science; Khalil, R.A., Ed.; Academic Press: Cambridge, MA, USA, 2017; Volume 147, pp. 1–73. [Google Scholar]
  36. Gutman, A.; Wasylyk, B. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. Embo J. 1990, 9, 2241–2246. [Google Scholar] [CrossRef] [PubMed]
  37. Jiménez, M.J.; Balbín, M.; López, J.M.; Alvarez, J.; Komori, T.; López-Otín, C. Collagenase 3 is a target of Cbfa1, a transcription factor of the runt gene family involved in bone formation. Mol. Cell. Biol. 1999, 19, 4431–4442. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Tardif, G.; Reboul, P.; Dupuis, M.; Geng, C.; Duval, N.; Pelletier, J.P.; Martel-Pelletier, J. Transforming growth factor-beta induced collagenase-3 production in human osteoarthritic chondrocytes is triggered by Smad proteins: Cooperation between activator protein-1 and PEA-3 binding sites. J. Rheumatol. 2001, 28, 1631–1639. [Google Scholar] [PubMed]
  39. Yu, H.; Fellows, A.; Foote, K.; Yang, Z.; Figg, N.; Littlewood, T.; Bennett, M. FOXO3a (Forkhead Transcription Factor O Subfamily Member 3a) Links Vascular Smooth Muscle Cell Apoptosis, Matrix Breakdown, Atherosclerosis, and Vascular Remodeling Through a Novel Pathway Involving MMP13 (Matrix Metalloproteinase 13). Arter. Thromb. Vasc. Biol. 2018, 38, 555–565. [Google Scholar] [CrossRef] [Green Version]
  40. Dumortier, M.; Ladam, F.; Damour, I.; Vacher, S.; Bièche, I.; Marchand, N.; de Launoit, Y.; Tulasne, D.; Chotteau-Lelièvre, A. ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis. Breast Cancer Res. 2018, 20, 73. [Google Scholar] [CrossRef] [Green Version]
  41. Kim, S.; Kang, M.; Ko, J. Small leucine zipper protein promotes the metastasis of castration-resistant prostate cancer through transcriptional regulation of matrix metalloproteinase-13. Carcinogenesis 2021, 42, 1089–1099. [Google Scholar] [CrossRef]
  42. Borden, P.; Solymar, D.; Sucharczuk, A.; Lindman, B.; Cannon, P.; Heller, R.A. Cytokine control of interstitial collagenase and collagenase-3 gene expression in human chondrocytes. J. Biol. Chem. 1996, 271, 23577–23581. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Jiang, C.; Xu, M.; Kuang, X.; Xiao, J.; Tan, M.; Xie, Y.; Xiao, Y.; Zhao, F.; Wu, Y. Treponema pallidum flagellins stimulate MMP-9 and MMP-13 expression via TLR5 and MAPK/NF-κB signaling pathways in human epidermal keratinocytes. Exp. Cell. Res. 2017, 361, 46–55. [Google Scholar] [CrossRef] [PubMed]
  44. Delany, A.M.; Rydziel, S.; Canalis, E. Autocrine down-regulation of collagenase-3 in rat bone cell cultures by insulin-like growth factors. Endocrinology 1996, 137, 4665–4670. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Uría, J.A.; Balbín, M.; López, J.M.; Alvarez, J.; Vizoso, F.; Takigawa, M.; López-Otín, C. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor. Am. J. Pathol. 1998, 153, 91–101. [Google Scholar] [CrossRef]
  46. Knäuper, V.; Bailey, L.; Worley, J.R.; Soloway, P.; Patterson, M.L.; Murphy, G. Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13. FEBS Lett. 2002, 532, 127–130. [Google Scholar] [CrossRef] [Green Version]
  47. Leeman, M.F.; McKay, J.A.; Murray, G.I. Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J. Clin. Pathol. 2002, 55, 758–762. [Google Scholar] [CrossRef] [Green Version]
  48. Moilanen, M.; Sorsa, T.; Stenman, M.; Nyberg, P.; Lindy, O.; Vesterinen, J.; Paju, A.; Konttinen, Y.T.; Stenman, U.H.; Salo, T. Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry 2003, 42, 5414–5420. [Google Scholar] [CrossRef]
  49. Gomez, D.E.; Alonso, D.F.; Yoshiji, H.; Thorgeirsson, U.P. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur. J. Cell Biol. 1997, 74, 111–122. [Google Scholar]
  50. Murphy, G. Tissue inhibitors of metalloproteinases. Genome Biol. 2011, 12, 233. [Google Scholar] [CrossRef]
  51. Gokulnath, M.; Swetha, R.; Thejaswini, G.; Shilpa, P.; Selvamurugan, N. Transforming growth factor-β1 regulation of ATF-3, c-Jun and JunB proteins for activation of matrix metalloproteinase-13 gene in human breast cancer cells. Int. J. Biol. Macromol. 2017, 94 Pt A, 370–377. [Google Scholar] [CrossRef]
  52. Enomoto, M.; Hayakawa, S.; Itsukushima, S.; Ren, D.Y.; Matsuo, M.; Tamada, K.; Oneyama, C.; Okada, M.; Takumi, T.; Nishita, M.; et al. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 2009, 28, 3197–3208. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Zhang, R.; Zhu, Z.; Shen, W.; Li, X.; Dhoomun, D.K.; Tian, Y. Golgi Membrane Protein 1 (GOLM1) Promotes Growth and Metastasis of Breast Cancer Cells via Regulating Matrix Metalloproteinase-13 (MMP13). Med. Sci. Monit. 2019, 25, 847–855. [Google Scholar] [CrossRef] [PubMed]
  54. Ala-aho, R.; Grenman, R.; Seth, P.; Kähäri, V.-M. Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells. Oncogene 2002, 21, 1187–1195. [Google Scholar] [CrossRef]
  55. Vaupel, P.; Multhoff, G. Fatal Alliance of Hypoxia-/HIF-1α-Driven Microenvironmental Traits Promoting Cancer Progression. Adv. Exp. Med. Biol. 2020, 1232, 169–176. [Google Scholar] [PubMed]
  56. Furman, D.; Campisi, J.; Verdin, E.; Carrera-Bastos, P.; Targ, S.; Franceschi, C.; Ferrucci, L.; Gilroy, D.W.; Fasano, A.; Miller, G.W.; et al. Chronic inflammation in the etiology of disease across the life span. Nat. Med. 2019, 25, 1822–1832. [Google Scholar] [CrossRef] [PubMed]
  57. Kusano, K.; Miyaura, C.; Inada, M.; Tamura, T.; Ito, A.; Nagase, H.; Kamoi, K.; Suda, T. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: Association of MMP induction with bone resorption. Endocrinology 1998, 139, 1338–1345. [Google Scholar] [CrossRef]
  58. Mengshol, J.A.; Vincenti, M.P.; Coon, C.I.; Barchowsky, A.; Brinckerhoff, C.E. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: Differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 2000, 43, 801–811. [Google Scholar] [CrossRef]
  59. Ibaragi, S.; Shimo, T.; Hassan, N.M.; Isowa, S.; Kurio, N.; Mandai, H.; Kodama, S.; Sasaki, A. Induction of MMP-13 expression in bone-metastasizing cancer cells by type I collagen through integrin α1β1 and α2β1-p38 MAPK signaling. Anticancer Res. 2011, 31, 1307–1313. [Google Scholar]
  60. Zeng, L.; Rong, X.F.; Li, R.H.; Wu, X.Y. Icariin inhibits MMP-1, MMP-3 and MMP-13 expression through MAPK pathways in IL-1β-stimulated SW1353 chondrosarcoma cells. Mol. Med. Rep. 2017, 15, 2853–2858. [Google Scholar] [CrossRef] [Green Version]
  61. Zhang, H.; Yang, Q.; Lian, X.; Jiang, P.; Cui, J. Hypoxia-Inducible Factor-1α (HIF-1α) Promotes Hypoxia-Induced Invasion and Metastasis in Ovarian Cancer by Targeting Matrix Metallopeptidase 13 (MMP13). Med. Sci. Monit. 2019, 25, 7202–7208. [Google Scholar] [CrossRef]
  62. Zhao, H.; Bo, Q.; Wang, W.; Wang, R.; Li, Y.; Chen, S.; Xia, Y.; Wang, W.; Wang, Y.; Zhu, K.; et al. CCL17-CCR4 axis promotes metastasis via ERK/MMP13 pathway in bladder cancer. J. Cell. Biochem. 2018, 120, 1979–1989. [Google Scholar] [CrossRef] [PubMed]
  63. Ou, B.; Zhao, J.; Guan, S.; Feng, H.; Wangpu, X.; Zhu, C.; Zong, Y.; Ma, J.; Sun, J.; Shen, X.; et al. CCR4 promotes metastasis via ERK/NF-κB/MMP13 pathway and acts downstream of TNF-α in colorectal cancer. Oncotarget 2016, 7, 47637–47649. [Google Scholar] [CrossRef] [Green Version]
  64. Kumamoto, K.; Fujita, K.; Kurotani, R.; Saito, M.; Unoki, M.; Hagiwara, N.; Shiga, H.; Bowman, E.D.; Yanaihara, N.; Okamura, S.; et al. ING2 is upregulated in colon cancer and increases invasion by enhanced MMP13 expression. Int. J. Cancer 2009, 125, 1306–1315. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Tan, M.; Gong, H.; Wang, J.; Tao, L.; Xu, D.; Bao, E.; Liu, Z.; Qiu, J. SENP2 regulates MMP13 expression in a bladder cancer cell line through SUMOylation of TBL1/TBLR1. Sci. Rep. 2015, 5, 13996. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Liu, S.; Huang, M.; Chen, Z.; Chen, J.; Chao, Q.; Yin, X.; Quan, M. FTO promotes cell proliferation and migration in esophageal squamous cell carcinoma through up-regulation of MMP13. Exp. Cell Res. 2020, 389, 111894. [Google Scholar] [CrossRef]
  67. Yamada, T.; Oshima, T.; Yoshihara, K.; Tamura, S.; Kanazawa, A.; Inagaki, D.; Yamamoto, N.; Sato, T.; Fujii, S.; Numata, K.; et al. Overexpression of MMP-13 Gene in Colorectal Cancer with Liver Metastasis. Anticancer Res. 2010, 30, 2693–2699. [Google Scholar]
  68. Yang, B.; Gao, J.; Rao, Z.; Shen, Q. Clinicopathological significance and prognostic value of MMP-13 expression in colorectal cancer. Scand. J. Clin. Lab. Investig. 2012, 72, 501–505. [Google Scholar] [CrossRef]
  69. Wang, S.W.; Tai, H.C.; Tang, C.H.; Lin, L.W.; Lin, T.H.; Chang, A.C.; Chen, P.C.; Chen, Y.H.; Wang, P.C.; Lai, Y.W.; et al. Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression. J. Cell. Physiol. 2021, 236, 3979–3990. [Google Scholar] [CrossRef]
  70. Etoh, T.; Inoue, H.; Yoshikawa, Y.; Barnard, G.F.; Kitano, S.; Mori, M. Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressiveness. Gut 2000, 47, 50–56. [Google Scholar] [CrossRef] [Green Version]
  71. Jiao, X.L.; Chen, D.; Wang, J.; Zhang, K. Clinical significance of serum matrix metalloproteinase-13 levels in patients with esophageal squamous cell carcinoma (ESCC). Eur. Rev. Med. Pharmacol. Sci. 2014, 18, 509–515. [Google Scholar]
  72. Wang, J.; Li, X.; Gao, X.; An, S.; Liu, H.; Liang, J.; Zhang, K.; Liu, Z.; Wang, J.; Chen, Z. Expression of MMP-13 is associated with invasion and metastasis of papillary thyroid carcinoma. Eur. Rev. Med. Pharmacol. Sci. 2013, 17, 427–435. [Google Scholar] [PubMed]
  73. del Casar Lizcano, J.; LO, G.S.; Gava, R.; Santisteban, D. Expression and clinical significance of collagenase-3 (MMP-13) in gastric cancer. Gastroenterol. Hepatol. 2003, 26, 1–7. [Google Scholar] [CrossRef]
  74. Lo, C.H.; Shay, G.; McGuire, J.J.; Li, T.; Shain, K.H.; Choi, J.Y.; Fuerst, R.; Roush, W.R.; Knapinska, A.M.; Fields, G.B.; et al. Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival. Cancer Res. 2021, 81, 2415–2428. [Google Scholar] [CrossRef] [PubMed]
  75. Boström, P.J.; Ravanti, L.; Reunanen, N.; Aaltonen, V.; Söderström, K.O.; Kähäri, V.M.; Laato, M. Expression of collagenase-3 (matrix metalloproteinase-13) in transitional-cell carcinoma of the urinary bladder. Int. J. Cancer 2000, 88, 417–423. [Google Scholar] [CrossRef]
  76. Kotepui, M.; Thawornkuno, C.; Chavalitshewinkoon-Petmitr, P.; Punyarit, P.; Petmitr, S. Quantitative real-time RT-PCR of ITGA7, SVEP1, TNS1, LPHN3, SEMA3G, KLB and MMP13 mRNA expression in breast cancer. Asian Pac. J. Cancer Prev. 2012, 13, 5879–5882. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Daja, M.M.; Niu, X.; Zhao, Z.; Brown, J.M.; Russell, P.J. Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines. Prostate Cancer Prostatic Dis. 2003, 6, 15–26. [Google Scholar] [CrossRef] [Green Version]
  78. Zhang, B.; Cao, X.; Liu, Y.; Cao, W.; Zhang, F.; Zhang, S.; Li, H.; Ning, L.; Fu, L.; Niu, Y.; et al. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer 2008, 8, 83. [Google Scholar] [CrossRef] [Green Version]
  79. Luukkaa, M.; Vihinen, P.; Kronqvist, P.; Vahlberg, T.; Pyrhönen, S.; Kähäri, V.M.; Grénman, R. Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer. Head Neck 2006, 28, 225–234. [Google Scholar] [CrossRef]
  80. Jiang, R.; Yu, S. Expression of MMP-13 and its correlation with prognosis in non-small cell lung cancer. Chin.-Ger. J. Clin. Oncol. 2008, 7, 142–144. [Google Scholar] [CrossRef]
  81. Morgia, G.; Falsaperla, M.; Malaponte, G.; Madonia, M.; Indelicato, M.; Travali, S.; Mazzarino, M.C. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol. Res. 2005, 33, 44–50. [Google Scholar] [CrossRef]
  82. Kalantari, E.; Abolhasani, M.; Roudi, R.; Farajollahi, M.M.; Farhad, S.; Madjd, Z.; Askarian-Amiri, S.; Mohsenzadegan, M. Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer. Int. J. Exp. Pathol. 2019, 100, 123–132. [Google Scholar] [CrossRef] [PubMed]
  83. Tanzer, M.L. Current concepts of extracellular matrix. J. Orthop. Sci. 2006, 11, 326–331. [Google Scholar] [CrossRef] [PubMed]
  84. Tanzer, M.L. Collagens and elastin: Structure and interactions. Curr. Opin. Cell Biol. 1989, 1, 968–973. [Google Scholar] [CrossRef]
  85. Iozzo, R.V. Matrix proteoglycans: From molecular design to cellular function. Annu. Rev. Biochem. 1998, 67, 609–652. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  86. Aumailley, M.; Smyth, N. The role of laminins in basement membrane function. J. Anat. 1998, 193 Pt 1, 1–21. [Google Scholar] [CrossRef] [PubMed]
  87. Wierzbicka-Patynowski, I.; Schwarzbauer, J.E. The ins and outs of fibronectin matrix assembly. J. Cell Sci. 2003, 116 Pt 16, 3269–3276. [Google Scholar] [CrossRef] [Green Version]
  88. Mott, J.D.; Werb, Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 2004, 16, 558–564. [Google Scholar] [CrossRef] [Green Version]
  89. Brown, N.H. Extracellular matrix in development: Insights from mechanisms conserved between invertebrates and vertebrates. Cold Spring Harb. Perspect. Biol. 2011, 3, a005082. [Google Scholar] [CrossRef] [Green Version]
  90. Agrez, M.; Chen, A.; Cone, R.I.; Pytela, R.; Sheppard, D. The alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain. J. Cell Biol. 1994, 127, 547–556. [Google Scholar] [CrossRef]
  91. Deryugina, E.I.; Quigley, J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25, 9–34. [Google Scholar] [CrossRef]
  92. Knäuper, V.; López-Otin, C.; Smith, B.; Knight, G.; Murphy, G. Biochemical characterization of human collagenase-3. J. Biol. Chem. 1996, 271, 1544–1550. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Knäuper, V.; Cowell, S.; Smith, B.; López-Otin, C.; O’Shea, M.; Morris, H.; Zardi, L.; Murphy, G. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J. Biol. Chem. 1997, 272, 7608–7616. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Fosang, A.J.; Last, K.; Knäuper, V.; Murphy, G.; Neame, P.J. Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Lett. 1996, 380, 17–20. [Google Scholar] [CrossRef] [Green Version]
  95. Ashworth, J.L.; Murphy, G.; Rock, M.J.; Sherratt, M.J.; Shapiro, S.D.; Shuttleworth, C.A.; Kielty, C.M. Fibrillin degradation by matrix metalloproteinases: Implications for connective tissue remodelling. Biochem. J. 1999, 340 Pt 1, 171–181. [Google Scholar] [CrossRef]
  96. Sasaki, T.; Göhring, W.; Mann, K.; Maurer, P.; Hohenester, E.; Knäuper, V.; Murphy, G.; Timpl, R. Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens. J. Biol. Chem. 1997, 272, 9237–9243. [Google Scholar] [CrossRef] [Green Version]
  97. Abety, A.N.; Pach, E.; Giebeler, N.; Fromme, J.E.; Aramadhaka, L.R.; Mauch, C.; Fox, J.W.; Zigrino, P. Loss of ADAM9 Leads to Modifications of the Extracellular Matrix Modulating Tumor Growth. Biomolecules 2020, 10, 1290. [Google Scholar] [CrossRef]
  98. McQuibban, G.A.; Butler, G.S.; Gong, J.-H.; Bendall, L.; Power, C.; Clark-Lewis, I.; Overall, C.M. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J. Biol. Chem. 2001, 276, 43503–43508. [Google Scholar] [CrossRef] [Green Version]
  99. McQuibban, G.A.; Gong, J.-H.; Tam, E.M.; McCulloch, C.A.; Clark-Lewis, I.; Overall, C.M. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000, 289, 1202–1206. [Google Scholar] [CrossRef]
  100. Deng, S.-J.; Bickett, D.M.; Mitchell, J.L.; Lambert, M.H.; Blackburn, R.K.; Carter, H.L.; Neugebauer, J.; Pahel, G.; Weiner, M.P.; Moss, M.L. Substrate specificity of human collagenase 3 assessed using a phage-displayed peptide library. J. Biol. Chem. 2000, 275, 31422–31427. [Google Scholar] [CrossRef] [Green Version]
  101. Hu, J.-Y.; Li, G.-C.; Wang, W.-M.; Zhu, J.-G.; Li, Y.-F.; Zhou, G.-H.; Sun, Q.-B. Transfection of colorectal cancer cells with chemokine MCP-3 (monocyte chemotactic protein-3) gene retards tumor growth and inhibits tumor metastasis. World J. Gastroenterol. 2002, 8, 1067–1072. [Google Scholar] [CrossRef]
  102. Viiklepp, K.; Nissinen, L.; Ojalill, M.; Riihilä, P.; Kallajoki, M.; Meri, S.; Heino, J.; Kähäri, V.M. C1r Upregulates Production of Matrix Metalloproteinase-13 and Promotes Invasion of Cutaneous Squamous Cell Carcinoma. J. Investig. Dermatol. 2021, 142, 1478–1488. [Google Scholar] [CrossRef] [PubMed]
  103. Fan, Y.; Gan, Y.; Shen, Y.; Cai, X.; Song, Y.; Zhao, F.; Yao, M.; Gu, J.; Tu, H. Leptin signaling enhances cell invasion and promotes the metastasis of human pancreatic cancer via increasing MMP-13 production. Oncotarget 2015, 6, 16120–16134. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  104. Ala-aho, R.; Ahonen, M.; George, S.J.; Heikkilä, J.; Grenman, R.; Kallajoki, M.; Kähäri, V.-M. Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo. Oncogene 2004, 23, 5111–5123. [Google Scholar] [CrossRef] [Green Version]
  105. Shah, M.; Huang, D.; Blick, T.; Connor, A.; Reiter, L.A.; Hardink, J.R.; Lynch, C.C.; Waltham, M.; Thompson, E.W. An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer. PLoS ONE 2012, 7, e29615. [Google Scholar] [CrossRef] [Green Version]
  106. Ala-aho, R.; Johansson, N.; Grenman, R.; Fusenig, N.E.; Lopez-Otin, C.; Kähäri, V.-M. Inhibition of collagenase-3 (MMP-13) expression in transformed human keratinocytes by interferon-γ is associated with activation of extracellular signal-regulated kinase-1, 2 and STAT1. Oncogene 2000, 19, 248–257. [Google Scholar] [CrossRef] [Green Version]
  107. Lu, P.; Takai, K.; Weaver, V.M.; Werb, Z. Extracellular matrix degradation and remodeling in development and disease. Cold Cold Spring Harb. Perspect. Biol. 2011, 3, a005058. [Google Scholar] [CrossRef]
  108. Whitelock, J.M.; Murdoch, A.D.; Iozzo, R.V.; Underwood, P.A. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem. 1996, 271, 10079–10086. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  109. Marinkovich, M.P.; Verrando, P.; Keene, D.R.; Meneguzzi, G.; Lunstrum, G.P.; Ortonne, J.P.; Burgeson, R.E. Basement membrane proteins kalinin and nicein are structurally and immunologically identical. Lab. Investig. 1993, 69, 295–299. [Google Scholar] [PubMed]
  110. Xia, Y.; Gil, S.G.; Carter, W.G. Anchorage mediated by integrin alpha6beta4 to laminin 5 (epiligrin) regulates tyrosine phosphorylation of a membrane-associated 80-kD protein. J. Cell Biol. 1996, 132, 727–740. [Google Scholar] [CrossRef]
  111. Jones, J.C.; Kurpakus, M.A.; Cooper, H.M.; Quaranta, V. A function for the integrin alpha 6 beta 4 in the hemidesmosome. Cell Regul. 1991, 2, 427–438. [Google Scholar] [CrossRef] [Green Version]
  112. Giannelli, G.; Falk-Marzillier, J.; Schiraldi, O.; Stetler-Stevenson, W.G.; Quaranta, V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997, 277, 225–228. [Google Scholar] [CrossRef]
  113. Koshikawa, N.; Giannelli, G.; Cirulli, V.; Miyazaki, K.; Quaranta, V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J. Cell Biol. 2000, 148, 615–624. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  114. Zhao, X.; Sun, B.; Li, Y.; Liu, Y.; Zhang, D.; Wang, X.; Gu, Q.; Zhao, J.; Dong, X.; Liu, Z.; et al. Dual effects of collagenase-3 on melanoma: Metastasis promotion and disruption of vasculogenic mimicry. Oncotarget 2015, 6, 8890–8899. [Google Scholar] [CrossRef] [PubMed]
  115. Knäuper, V.; Smith, B.; López-Otin, C.; Murphy, G. Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13). Eur. J. Biochem. 1997, 248, 369–373. [Google Scholar] [CrossRef] [PubMed]
  116. Dreier, R.; Grässel, S.; Fuchs, S.; Schaumburger, J.; Bruckner, P. Pro-MMP-9 is a specific macrophage product and is activated by osteoarthritic chondrocytes via MMP-3 or a MT1-MMP/MMP-13 cascade. Exp. Cell Res. 2004, 297, 303–312. [Google Scholar] [CrossRef]
  117. Hernández Ríos, M.; Sorsa, T.; Obregón, F.; Tervahartiala, T.; Valenzuela, M.A.; Pozo, P.; Dutzan, N.; Lesaffre, E.; Molas, M.; Gamonal, J. Proteolytic roles of matrix metalloproteinase (MMP)-13 during progression of chronic periodontitis: Initial evidence for MMP-13/MMP-9 activation cascade. J. Clin. Periodontol. 2009, 36, 1011–1017. [Google Scholar] [CrossRef]
  118. Roche, J. The Epithelial-to-Mesenchymal Transition in Cancer. Cancers 2018, 10, 52. [Google Scholar] [CrossRef] [Green Version]
  119. Mittal, V. Epithelial Mesenchymal Transition in Tumor Metastasis. Annu. Rev. Pathol. 2018, 13, 395–412. [Google Scholar] [CrossRef]
  120. Kim, B.N.; Ahn, D.H.; Kang, N.; Yeo, C.D.; Kim, Y.K.; Lee, K.Y.; Kim, T.-J.; Lee, S.H.; Park, M.S.; Yim, H.W.; et al. TGF-β induced EMT and stemness characteristics are associated with epigenetic regulation in lung cancer. Sci. Rep. 2020, 10, 10597. [Google Scholar] [CrossRef]
  121. Illman, S.A.; Lehti, K.; Keski-Oja, J.; Lohi, J. Epilysin (MMP-28) induces TGF-beta mediated epithelial to mesenchymal transition in lung carcinoma cells. J. Cell Sci. 2006, 119 Pt 18, 3856–3865. [Google Scholar] [CrossRef] [Green Version]
  122. D’Angelo, M.; Billings, P.C.; Pacifici, M.; Leboy, P.S.; Kirsch, T. Authentic matrix vesicles contain active metalloproteases (MMP). A role for matrix vesicle-associated MMP-13 in activation of transforming growth factor-beta. J. Biol. Chem. 2001, 276, 11347–11353. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  123. Nannuru, K.C.; Futakuchi, M.; Varney, M.L.; Vincent, T.M.; Marcusson, E.G.; Singh, R.K. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface. Cancer Res. 2010, 70, 3494–3504. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  124. Banyard, J.; Bielenberg, D.R. The role of EMT and MET in cancer dissemination. Connect. Tissue Res. 2015, 56, 403–413. [Google Scholar] [CrossRef] [Green Version]
  125. Barillari, G. The Impact of Matrix Metalloproteinase-9 on the Sequential Steps of the Metastatic Process. Int. J. Mol. Sci. 2020, 21, 4526. [Google Scholar] [CrossRef] [PubMed]
  126. Folgueras, A.R.; Pendás, A.M.; Sánchez, L.M.; López-Otín, C. Matrix metalloproteinases in cancer: From new functions to improved inhibition strategies. Int. J. Dev. Biol. 2004, 48, 411–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  127. Mondal, S.; Adhikari, N.; Banerjee, S.; Amin, S.A.; Jha, T. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview. Eur. J. Med. Chem. 2020, 194, 112260. [Google Scholar] [CrossRef] [PubMed]
  128. Mendonsa, A.M.; VanSaun, M.N.; Ustione, A.; Piston, D.W.; Fingleton, B.M.; Gorden, D.L. Host and tumor derived MMP13 regulate extravasation and establishment of colorectal metastases in the liver. Mol. Cancer 2015, 14, 49. [Google Scholar] [CrossRef] [Green Version]
  129. Kolb, A.D.; Bussard, K.M. The Bone Extracellular Matrix as an Ideal Milieu for Cancer Cell Metastases. Cancers 2019, 11, 1020. [Google Scholar] [CrossRef] [Green Version]
  130. Lu, P.; Weaver, V.M.; Werb, Z. The extracellular matrix: A dynamic niche in cancer progression. J. Cell Biol. 2012, 196, 395–406. [Google Scholar] [CrossRef]
  131. Ohshiba, T.; Miyaura, C.; Inada, M.; Ito, A. Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Br. J. Cancer 2003, 88, 1318–1326. [Google Scholar] [CrossRef] [Green Version]
  132. Page-McCaw, A.; Ewald, A.J.; Werb, Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 2007, 8, 221–233. [Google Scholar] [CrossRef] [PubMed]
  133. Lafleur, M.A.; Drew, A.F.; de Sousa, E.L.; Blick, T.; Bills, M.; Walker, E.C.; Williams, E.D.; Waltham, M.; Thompson, E.W. Upregulation of matrix metalloproteinases (MMPs) in breast cancer xenografts: A major induction of stromal MMP-13. Int. J. Cancer 2005, 114, 544–554. [Google Scholar] [CrossRef] [PubMed]
  134. Morrison, C.; Mancini, S.; Cipollone, J.; Kappelhoff, R.; Roskelley, C.; Overall, C. Microarray and proteomic analysis of breast cancer cell and osteoblast co-cultures: Role of osteoblast matrix metalloproteinase (MMP)-13 in bone metastasis. J. Biol. Chem. 2011, 286, 34271–34285. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  135. Ibaragi, S.; Shimo, T.; Iwamoto, M.; Hassan, N.M.; Kodama, S.; Isowa, S.; Sasaki, A. Parathyroid hormone-related peptide regulates matrix metalloproteinase-13 gene expression in bone metastatic breast cancer cells. Anticancer Res. 2010, 30, 5029–5036. [Google Scholar] [PubMed]
  136. Pivetta, E.; Scapolan, M.; Pecolo, M.; Wassermann, B.; Abu-Rumeileh, I.; Balestreri, L.; Borsatti, E.; Tripodo, C.; Colombatti, A.; Spessotto, P. MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases. Breast Cancer Res. 2011, 13, R105. [Google Scholar] [CrossRef] [Green Version]
  137. Fu, J.; Li, S.; Feng, R.; Ma, H.; Sabeh, F.; Roodman, G.D.; Mapara, M.; Weiss, S.J.; Lentzsch, S. Matrix Metalloproteinase 13 (MMP13) Upregulation Is Essential for Multiple Myeloma Related Bone Lytic Lesion. Blood 2012, 120, 4025. [Google Scholar] [CrossRef]
  138. Fu, J.; Li, S.; Feng, R.; Ma, H.; Sabeh, F.; Roodman, G.D.; Wang, J.; Robinson, S.; Guo, X.E.; Lund, T.; et al. Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease. J. Clin. Investig. 2016, 126, 1759–1772. [Google Scholar] [CrossRef] [Green Version]
  139. Fuerst, R.; Yong Choi, J.; Knapinska, A.M.; Smith, L.; Cameron, M.D.; Ruiz, C.; Fields, G.B.; Roush, W.R. Development of matrix metalloproteinase-13 inhibitors—A structure-activity/structure-property relationship study. Bioorg. Med. Chem. 2018, 26, 4984–4995. [Google Scholar] [CrossRef]
  140. Liu, Y.; Cao, X. Characteristics and Significance of the Pre-metastatic Niche. Cancer Cell 2016, 30, 668–681. [Google Scholar] [CrossRef] [Green Version]
  141. Hiratsuka, S.; Watanabe, A.; Aburatani, H.; Maru, Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 2006, 8, 1369–1375. [Google Scholar] [CrossRef]
  142. Kaplan, R.N.; Riba, R.D.; Zacharoulis, S.; Bramley, A.H.; Vincent, L.; Costa, C.; MacDonald, D.D.; Jin, D.K.; Shido, K.; Kerns, S.A.; et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438, 820–827. [Google Scholar] [CrossRef] [PubMed]
  143. Hiratsuka, S.; Watanabe, A.; Sakurai, Y.; Akashi-Takamura, S.; Ishibashi, S.; Miyake, K.; Shibuya, M.; Akira, S.; Aburatani, H.; Maru, Y. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 2008, 10, 1349–1355. [Google Scholar] [CrossRef] [PubMed]
  144. Bond, M.; Fabunmi, R.P.; Baker, A.H.; Newby, A.C. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription factor NF-kappa B. FEBS Lett. 1998, 435, 29–34. [Google Scholar] [CrossRef] [Green Version]
  145. Kitamura, T.; Qian, B.-Z.; Pollard, J.W. Immune cell promotion of metastasis. Nat. Rev. Immunol. 2015, 15, 73–86. [Google Scholar] [CrossRef]
  146. Heissig, B.; Hattori, K.; Dias, S.; Friedrich, M.; Ferris, B.; Hackett, N.R.; Crystal, R.G.; Besmer, P.; Lyden, D.; Moore, M.A.; et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002, 109, 625–637. [Google Scholar] [CrossRef] [Green Version]
  147. Erler, J.T.; Bennewith, K.L.; Cox, T.R.; Lang, G.; Bird, D.; Koong, A.; Le, Q.-T.; Giaccia, A.J. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009, 15, 35–44. [Google Scholar] [CrossRef] [Green Version]
  148. Boileau, C.; Pelletier, J.P.; Tardif, G.; Fahmi, H.; Laufer, S.; Lavigne, M.; Martel-Pelletier, J. The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway. Ann. Rheum. Dis. 2005, 64, 891–898. [Google Scholar] [CrossRef] [Green Version]
  149. Zhang, L.; Yu, D. Exosomes in cancer development, metastasis, and immunity. Biochim. Biophys. Acta Rev. Cancer 2019, 1871, 455–468. [Google Scholar] [CrossRef]
  150. Liu, Y.; Gu, Y.; Cao, X. The exosomes in tumor immunity. Oncoimmunology 2015, 4, e1027472. [Google Scholar] [CrossRef] [Green Version]
  151. Costa-Silva, B.; Aiello, N.M.; Ocean, A.J.; Singh, S.; Zhang, H.; Thakur, B.K.; Becker, A.; Hoshino, A.; Mark, M.T.; Molina, H.; et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 2015, 17, 816–826. [Google Scholar] [CrossRef]
  152. Shan, Y.; You, B.; Shi, S.; Shi, W.; Zhang, Z.; Zhang, Q.; Gu, M.; Chen, J.; Bao, L.; Liu, D.; et al. Hypoxia-Induced Matrix Metalloproteinase-13 Expression in Exosomes from Nasopharyngeal Carcinoma Enhances Metastases. Cell Death Dis. 2018, 9, 382. [Google Scholar] [CrossRef] [PubMed]
  153. Shah, A.A.; Kamal, M.A.; Akhtar, S. Tumor Angiogenesis and VEGFR-2: Mechanism, Pathways and Current Biological Therapeutic Interventions. Curr. Drug Metab. 2021, 22, 50–59. [Google Scholar] [CrossRef] [PubMed]
  154. Li, T.; Kang, G.; Wang, T.; Huang, H. Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol. Lett. 2018, 16, 687–702. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  155. Nishida, N.; Yano, H.; Nishida, T.; Kamura, T.; Kojiro, M. Angiogenesis in cancer. Vasc. Health Risk Manag. 2006, 2, 213–219. [Google Scholar] [CrossRef]
  156. Welti, J.; Loges, S.; Dimmeler, S.; Carmeliet, P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J. Clin. Investig. 2013, 123, 3190–3200. [Google Scholar] [CrossRef] [Green Version]
  157. de la Puente, P.; Muz, B.; Azab, F.; Azab, A.K. Cell trafficking of endothelial progenitor cells in tumor progression. Clin. Cancer Res. 2013, 19, 3360–3368. [Google Scholar] [CrossRef] [Green Version]
  158. Ferrara, N.; Adamis, A.P. Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. 2016, 15, 385–403. [Google Scholar] [CrossRef] [Green Version]
  159. Eelen, G.; de Zeeuw, P.; Simons, M.; Carmeliet, P. Endothelial cell metabolism in normal and diseased vasculature. Circ. Res. 2015, 116, 1231–1244. [Google Scholar] [CrossRef]
  160. Moschetta, M.; Mishima, Y.; Sahin, I.; Manier, S.; Glavey, S.; Vacca, A.; Roccaro, A.M.; Ghobrial, I.M. Role of endothelial progenitor cells in cancer progression. Biochim. Biophys. Acta 2014, 1846, 26–39. [Google Scholar] [CrossRef]
  161. Liekens, S.; De Clercq, E.; Neyts, J. Angiogenesis: Regulators and clinical applications. Biochem. Pharmacol. 2001, 61, 253–270. [Google Scholar] [CrossRef]
  162. Milkiewicz, M.; Ispanovic, E.; Doyle, J.L.; Haas, T.L. Regulators of angiogenesis and strategies for their therapeutic manipulation. Int. J. Biochem. Cell Biol. 2006, 38, 333–357. [Google Scholar] [CrossRef] [PubMed]
  163. Quintero-Fabián, S.; Arreola, R.; Becerril-Villanueva, E.; Torres-Romero, J.C.; Arana-Argáez, V.; Lara-Riegos, J.; Ramírez-Camacho, M.A.; Alvarez-Sánchez, M.E. Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Front. Oncol. 2019, 9, 1370. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  164. Zijlstra, A.; Aimes, R.T.; Zhu, D.; Regazzoni, K.; Kupriyanova, T.; Seandel, M.; Deryugina, E.I.; Quigley, J.P. Collagenolysis-dependent angiogenesis mediated by matrix metalloproteinase-13 (collagenase-3). J. Biol. Chem. 2004, 279, 27633–27645. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  165. Perumal, S.; Antipova, O.; Orgel, J.P. Collagen fibril architecture, domain organization, and triple-helical conformation govern its proteolysis. Proc. Natl. Acad. Sci. USA 2008, 105, 2824–2829. [Google Scholar] [CrossRef] [Green Version]
  166. Seandel, M.; Noack-Kunnmann, K.; Zhu, D.; Aimes, R.T.; Quigley, J.P. Growth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen. Blood 2001, 97, 2323–2332. [Google Scholar] [CrossRef] [Green Version]
  167. Rundhaug, J.E. Matrix metalloproteinases and angiogenesis. J. Cell. Mol. Med. 2005, 9, 267–285. [Google Scholar] [CrossRef]
  168. Kudo, Y.; Iizuka, S.; Yoshida, M.; Tsunematsu, T.; Kondo, T.; Subarnbhesaj, A.; Deraz, E.M.; Siriwardena, S.B.; Tahara, H.; Ishimaru, N.; et al. Matrix metalloproteinase-13 (MMP-13) directly and indirectly promotes tumor angiogenesis. J. Biol. Chem. 2012, 287, 38716–38728. [Google Scholar] [CrossRef] [Green Version]
  169. Lederle, W.; Hartenstein, B.; Meides, A.; Kunzelmann, H.; Werb, Z.; Angel, P.; Mueller, M.M. MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis 2010, 31, 1175–1184. [Google Scholar] [CrossRef] [Green Version]
  170. Xu, L.; Sun, K.; Xia, M.; Li, X.; Lu, Y. MMP13 Regulates Aggressiveness of Pediatric Multiple Myeloma Through VEGF-C. Cell. Physiol. Biochem. 2015, 36, 509–516. [Google Scholar] [CrossRef]
Cancers 14 03263 g001 550
Figure 1. MMP-13 structure: MMP-13 consists of a highly conserved signal peptide, a pro-domain, a catalytic domain, a proline-rich hinge region and a C-terminal hemopexin-like domain (top panel). The cysteine residue (Cys 77) shown in grey within the pro-domain is linked to the catalytic zinc ion within the catalytic domain in pro-active MMP-13. The bottom panel shows the MMP-13 catalytic domain (PDB 2OW9). The structural zinc ion is in blue, the catalytic zinc ion is in green, and the three calcium ions are in orange. Three histidine residues, which bind to the catalytic zinc ion, are shown as hexagons.
Figure 1. MMP-13 structure: MMP-13 consists of a highly conserved signal peptide, a pro-domain, a catalytic domain, a proline-rich hinge region and a C-terminal hemopexin-like domain (top panel). The cysteine residue (Cys 77) shown in grey within the pro-domain is linked to the catalytic zinc ion within the catalytic domain in pro-active MMP-13. The bottom panel shows the MMP-13 catalytic domain (PDB 2OW9). The structural zinc ion is in blue, the catalytic zinc ion is in green, and the three calcium ions are in orange. Three histidine residues, which bind to the catalytic zinc ion, are shown as hexagons.
Cancers 14 03263 g001
Cancers 14 03263 g002 550
Figure 2. Regulation of MMP-13 expression and secretion in pathophysiology: MMP-13 expression and secretion in physiological conditions are tightly controlled by transcription factors and TIMPs. Various transcription factors bind directly to the MMP-13 promoter region. In cancer, the tight control of MMP-13 expression is disrupted by intrinsic and extrinsic mechanisms. Intrinsic mechanisms include changes of expression of oncogenes (e.g., Ror2) and tumour suppressor genes (e.g., p53). Extrinsic mechanisms include hypoxia and inflammation-induced secretion of cytokines and chemokines that activate downstream MARK signalling and NF-κB nuclear translocation to regulate MMP-13 expression. MMP-13 secretion is regulated by endocytosis through endocytic receptor LRP1 and subsequent degradation in lysosomes.
Figure 2. Regulation of MMP-13 expression and secretion in pathophysiology: MMP-13 expression and secretion in physiological conditions are tightly controlled by transcription factors and TIMPs. Various transcription factors bind directly to the MMP-13 promoter region. In cancer, the tight control of MMP-13 expression is disrupted by intrinsic and extrinsic mechanisms. Intrinsic mechanisms include changes of expression of oncogenes (e.g., Ror2) and tumour suppressor genes (e.g., p53). Extrinsic mechanisms include hypoxia and inflammation-induced secretion of cytokines and chemokines that activate downstream MARK signalling and NF-κB nuclear translocation to regulate MMP-13 expression. MMP-13 secretion is regulated by endocytosis through endocytic receptor LRP1 and subsequent degradation in lysosomes.
Cancers 14 03263 g002
Cancers 14 03263 g003 550
Figure 3. The action of MMP-13 in cancer progression and metastasis: MMP-13, produced by cancer cells and stromal fibroblasts, cleaves ECM and leads to ECM remodelling and liberation of ECM-bound growth factors and angiogenic factors that promote tumour cell proliferation, invasion, EMT and angiogenesis at primary tumour sites. At distant metastasis sites, MMP-13-mediated ECM remodelling and release of growth factors and collagen IV peptides help the recruitment of immune cells to the pre-metastatic niche and the establishment of a favourable metastasis environment.
Figure 3. The action of MMP-13 in cancer progression and metastasis: MMP-13, produced by cancer cells and stromal fibroblasts, cleaves ECM and leads to ECM remodelling and liberation of ECM-bound growth factors and angiogenic factors that promote tumour cell proliferation, invasion, EMT and angiogenesis at primary tumour sites. At distant metastasis sites, MMP-13-mediated ECM remodelling and release of growth factors and collagen IV peptides help the recruitment of immune cells to the pre-metastatic niche and the establishment of a favourable metastasis environment.
Cancers 14 03263 g003
Table
Table 1. MMP-13 expression in common cancer and its function and clinical significance.
Table 1. MMP-13 expression in common cancer and its function and clinical significance.
Cancer TypeExpression LevelFunction and Clinical SignificanceReferences
Breast cancerIncreasedIncreased tumour growth, invasion and metastasis; potential diagnostic biomarker[13]
Prostate cancerIncreasedIncreased tumour differentiation, invasion and metastasis; diagnostic biomarker; poor prognosis[69,81,82]
Bladder cancerIncreasedIncreased tumour invasion and metastasis; poor prognosis[75]
Colorectal cancerIncreasedIncreased tumour growth, invasion and metastasis; poor prognosis[47,68]
Oesophageal cancerIncreasedPromoted cancer aggressiveness; poor prognosis[70,71]
Head and neck cancerIncreasedIncreased tumour invasion and metastasis; poor prognosis[14]
Lung cancerIncreasedPromoted lymph node metastasis; poor survival[80]
Oesophageal cancerIncreasedPromoted cancer aggressiveness; poor prognosis[70]
Gastric cancerIncreasedIncreased tumour invasion and metastasis; poor prognosis[73]
Thyroid cancerIncreasedIncreased tumour invasion and metastasis; poor prognosis[72]
Multiple MyelomaIncreasedPromoted tumour growth and MM-induced osteolysis; poor prognosis[74]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Li, S.; Pritchard, D.M.; Yu, L.-G. Regulation and Function of Matrix Metalloproteinase-13 in Cancer Progression and Metastasis. Cancers 2022, 14, 3263. https://doi.org/10.3390/cancers14133263

AMA Style

Li S, Pritchard DM, Yu L-G. Regulation and Function of Matrix Metalloproteinase-13 in Cancer Progression and Metastasis. Cancers. 2022; 14(13):3263. https://doi.org/10.3390/cancers14133263

Chicago/Turabian Style

Li, Shun, David Mark Pritchard, and Lu-Gang Yu. 2022. "Regulation and Function of Matrix Metalloproteinase-13 in Cancer Progression and Metastasis" Cancers 14, no. 13: 3263. https://doi.org/10.3390/cancers14133263

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop